234 related articles for article (PubMed ID: 27570484)
1. An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation.
Li H; Sheng C; Liu H; Liu G; Du X; Du J; Zhan L; Li P; Yang C; Qi L; Wang J; Yang X; Jia L; Xie J; Wang L; Hao R; Xu D; Tong Y; Zhou Y; Zhou J; Sun Y; Li Q; Qiu S; Song H
Int J Biol Sci; 2016; 12(9):1104-13. PubMed ID: 27570484
[TBL] [Abstract][Full Text] [Related]
2. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.
Fei L; Sun S; Yang Q; Huang Y; Li Q; Tao S; Chen L
Discov Med; 2024 Jun; 36(185):1169-1179. PubMed ID: 38926103
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
[TBL] [Abstract][Full Text] [Related]
5. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
Zhu W; Xie K; Xu Y; Wang L; Chen K; Zhang L; Fang J
Virus Res; 2016 Jun; 217():125-32. PubMed ID: 27049051
[TBL] [Abstract][Full Text] [Related]
7. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
Peng C; Lu M; Yang D
Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
[TBL] [Abstract][Full Text] [Related]
9. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.
Wang J; Xu ZW; Liu S; Zhang RY; Ding SL; Xie XM; Long L; Chen XM; Zhuang H; Lu FM
World J Gastroenterol; 2015 Aug; 21(32):9554-65. PubMed ID: 26327763
[TBL] [Abstract][Full Text] [Related]
10. Application of CRISPR/Cas9 Technology to HBV.
Lin G; Zhang K; Li J
Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
[TBL] [Abstract][Full Text] [Related]
11. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
Liu X; Hao R; Chen S; Guo D; Chen Y
J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
[TBL] [Abstract][Full Text] [Related]
13. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
Yang YC; Yang HC
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
[TBL] [Abstract][Full Text] [Related]
14. The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication.
Wang J; Chen R; Zhang R; Ding S; Zhang T; Yuan Q; Guan G; Chen X; Zhang T; Zhuang H; Nunes F; Block T; Liu S; Duan Z; Xia N; Xu Z; Lu F
Theranostics; 2017; 7(12):3090-3105. PubMed ID: 28839466
[TBL] [Abstract][Full Text] [Related]
15. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus.
Sakuma T; Masaki K; Abe-Chayama H; Mochida K; Yamamoto T; Chayama K
Genes Cells; 2016 Nov; 21(11):1253-1262. PubMed ID: 27659023
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus.
Zhen S; Hua L; Liu YH; Gao LC; Fu J; Wan DY; Dong LH; Song HF; Gao X
Gene Ther; 2015 May; 22(5):404-12. PubMed ID: 25652100
[TBL] [Abstract][Full Text] [Related]
17. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
[TBL] [Abstract][Full Text] [Related]
18. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
[TBL] [Abstract][Full Text] [Related]
19. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
[TBL] [Abstract][Full Text] [Related]
20. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.
Seeger C; Sohn JA
Mol Ther; 2016 Aug; 24(7):1258-66. PubMed ID: 27203444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
